Unither To Acquire UCB New York Plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Unither To Acquire UCB New York Plant


Unither Pharmaceuticals, a sterile unit-dose manufacturer, will acquire an UCB pharmaceutical plant in Rochester, NY. The plant employs 250 people and mainly manufacturers liquid pharmaceutical products. This acquisition is a part of Unither's strategy to become a pharmaceutical global player and particularly in blow/fill/seal (BFS) technology. Under the agreement, Unither will continue manufacturing UCB products, and all Rochester's employees will be offered the opportunity to work for Unither. While manufacturing UCB products, Unither intends to install BFS and stick-pack technologies in the Rochester plant to provide its clients or US prospects with locally made products.The transaction is expected to be completed in the fourth quarter of this year, according to a Unither press release.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here